EyePoint Pharmaceuticals announced that it has signed an interim agreement with the U.S. Department of Veteran Affairs (VA) for Dexycu and Yutiq to be included on the Federal Supply Schedule (FSS), providing U.S. veterans and other federal government agencies with access to both products. The VA FSS contract will extend access to Eyepoint products to over 9 million VA beneficiaries and others within the federal system. The final VA contract is expected to be executed in the next few months and have a 5-year term.
“This new agreement with the VA further extends the commercial reach of Dexycu and Yutiq to patients suffering from ocular diseases in areas of high unmet medical need,” Nancy Lurker, President and CEO of EyePoint Pharmaceuticals, said in a company news release. “Our commercial launch efforts have yielded a positive reception with physicians and an increased product demand from ambulatory surgical centers for Dexycu and uveitis specialists for Yutiq. We are extremely proud that U.S. veterans and other federal employees will now be offered access to our innovative ophthalmic products, increasing patient access to an additional 9 million beneficiaries.”